DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases.

DOTA-Zoledronate is a promising agent for the development of other future-oriented radionuclide therapy concepts for personalized nuclear oncology[1].

1908409-18-6

C23H41N7O14P2

701.564

DOTA Zoledronate

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years